Samsung Biologics

Samsung Biologics is a South Korean biotechnology firm based in Songdo, Incheon, South Korea. Samsung Group's biotech branch provides contract development and manufacturing (CDMO) services to the biopharmaceutical industry.

For COVID-19 therapies, the business has collaborated with GlaxoSmithKline, Eli Lilly, and AstraZeneca. During the COVID-19 pandemic, Samsung Biologics collaborated with Moderna to fill-finish, packaging and labeling its mRNA vaccine, Spikevax, and Greenlight Biosciences on manufacturing of mRNA vaccine medicinal substance candidates.

Samsung Biologics is a fully integrated contract development and manufacturing organization that provides cutting-edge contract development and manufacturing services. Samsung Biologics is an award-winning partner of choice, with proven regulatory approvals, the largest capacity, and the fastest throughput. It is uniquely able to support the development and manufacturing of biologics products at every stage of the process while meeting the evolving needs of biopharmaceutical companies worldwide.

Samsung Biologics is a dependable partner in the clinical and commercial manufacture, aseptic fill/finish, and analytical testing. From the start of their collaboration, you will have a dedicated project management team to walk you through the whole product development and manufacturing process. They are committed to operational excellence in cGMP production and quality assurance to provide value to their clients.

Founded: 2011
Headquarters: Songdo, Incheon, South Korea
Key people: John Rim, President and CEO

Website: https://samsungbiologics.com/